(Q38545589)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26165756%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

review article

1 reference

title

Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26165756%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26165756%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

author name string

Miriam T Levine

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26165756%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Eunice Ann H Wong

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26165756%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Donald P Levine

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26165756%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

publication date

12 July 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26165756%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anti-infective Therapy

19 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26165756%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26165756%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26165756%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

page(s)

1265-1278

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26165756%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

cites work

Vancomycin: a history

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Chemistry, Biology, and Medicine of the Glycopeptide Antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Glycopeptide antibiotics: back to the future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Vancomycin revisited - 60 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Structure and mechanism of action of teicoplanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

High-level vancomycin-resistant enterococci causing hospital infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Vancomycin-resistant enterococci: mechanisms and clinical observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Mechanisms of resistance and clinical relevance of resistance to β-lactams, glycopeptides, and fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

The rise of the Enterococcus: beyond vancomycin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Resistance to antibiotics targeted to the bacterial cell wall

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

VRSA-doomsday superbug or damp squib?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Fitness cost of VanA-type vancomycin resistance in methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Impact of vancomycin minimum inhibitory concentration on clinical outcomes of patients with vancomycin-susceptible Staphylococcus aureus infections: a meta-analysis and meta-regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Retrospective observational study comparing vancomycin versus daptomycin as initial therapy for Staphylococcus aureus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Vancomycin: we can't get there from here.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Pharmacodynamics: relation to antimicrobial resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

The pharmacokinetic and pharmacodynamic properties of vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Are vancomycin trough concentrations adequate for optimal dosing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

In vivo pharmacodynamic activity of the glycopeptide dalbavancin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Review of dalbavancin, a novel semisynthetic lipoglycopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Postantibiotic effects of telavancin against 16 gram-positive organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Telavancin: a novel lipoglycopeptide antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Vancomycin dosing and monitoring 2 years after the guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Clinical pharmacokinetics of vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Removal of vancomycin by high-flux hemodialysis membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Vancomycin dosing in patients on intermittent hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Human organ/tissue growth algorithms that include obese individuals and black/white population organ weight similarities from autopsy data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Clinical pharmacokinetics of teicoplanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

The use and therapeutic drug monitoring of teicoplanin in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Vancomycin nephrotoxicity: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Defining risk factors for red man syndrome in children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Vancomycin-induced neutropenia: is it dose- or duration-related?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Vancomycin-induced neutropenia associated with fever: similarities between two immune-mediated drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Teicoplanin-induced hypersensitivity syndrome with a preceding vancomycin-induced neutropenia: a case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Risk of hepatic events in patients treated with vancomycin in clinical studies: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

High-dose regimen to achieve novel target trough concentration in teicoplanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Severe tremor due to vancomycin therapy: a case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Complete heart block in a patient with acute lymphoblastic leukaemia: teicoplanin as a possible cause and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Teicoplanin-induced complete AV-block in a heart transplant recipient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1068118

10.1586/14787210.2015.1068118

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26165756%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

1 reference